Frontline and Subsequent Treatment Planning for Metastatic EGFR-Positive NSCLC

Dr. Konduri provides a clinician's overview of the frontline to subsequent-line treatment framework for metastatic EGFR-positive NSCLC. Patient assessment at each visit includes not only laboratory values and organ function but also social circumstances, travel capacity, frailty, and ability to tolerate intensive combination regimens versus monotherapy. Clinical trial participation is encouraged at all lines.

Current standard-of-care frontline combination approaches offer meaningful improvements in both short-term and long-term outcomes compared to historical monotherapy. Frontline treatment selection directly affects subsequent-line options, making the initial choice consequential beyond the immediate therapeutic benefit. When frontline therapy stops yielding significant benefit, second-line therapy is selected based on available evidence and the mechanisms of prior treatment.

Elizabeth Dennis describes the communication approach when patients are overwhelmed by new diagnoses and complex information: encouraging one step at a time, ensuring patients understand their specific diagnosis and treatment plan, building a support system including caregivers and community connections, and aligning around individualized goals, such as what success looks like for the patient as well as for the care team.

She addresses the fear associated with the word chemotherapy directly: many patients' fears are based on others' prior experiences, which may reflect older regimens or very different clinical circumstances. Explaining the specific therapy, its goals, its expected side effect profile, and the proactive management strategies available helps patients feel informed, supported, and confident rather than fearful. Patients should understand that no 2 treatment experiences are identical, and that their care team is available around the clock through telephone and secure patient portal messaging to address any concerns that arise.

Lynn Abbott-McCloud confirms that peer discussions at LiveLung meetings, where patients share their own experiences across the full spectrum, from very difficult to manageable, are often more reassuring to newly diagnosed patients than any formal presentation, because they convey the reality that individual experiences vary widely.